Medicine – Systemic Sclerosis and Scleroderma Renal Crisis

Systemic sclerosis is a chronic autoimmune connective tissue disease characterised by vascular dysfunction, immune activation, and progressive fibrosis affecting the skin and multiple internal organs.

Renal involvement is particularly important because systemic sclerosis can cause scleroderma renal crisis, a medical emergency associated with abrupt severe hypertension, acute kidney injury, and microangiopathic haemolytic anaemia.

1. Scleroderma Renal Crisis

The renal presentation described in the original note refers specifically to:

Scleroderma renal crisis.

This is one of the most serious complications of systemic sclerosis.

It typically presents with:

Sudden severe hypertension.

Rapidly rising creatinine.

Acute kidney injury.

Microangiopathic haemolytic anaemia.

2. Accelerated or Malignant Hypertension

Patients may develop:

Abrupt severe hypertension.

Older terminology often refers to:

Accelerated hypertension

or

Malignant hypertension.

Modern terminology generally prefers:

Hypertensive emergency

when severe blood pressure elevation is accompanied by acute target-organ damage.

3. Clinical Consequences of Severe Hypertension

Severe hypertension may produce:

Headache.

Visual disturbance.

Confusion.

Seizures.

Heart failure.

Pulmonary oedema.

Hypertensive retinopathy.

The kidney itself is one of the major target organs.

4. Acute Kidney Injury

Scleroderma renal crisis causes:

Rapid deterioration in renal function.

The older abbreviation:

ARF – acute renal failure

is now more commonly replaced by:

AKI – acute kidney injury.

Laboratory findings typically include a rapidly increasing:

Serum creatinine.

5. Microangiopathic Haemolytic Anaemia

A classic associated feature is:

Microangiopathic haemolytic anaemia, or MAHA.

This results from red blood cells being mechanically damaged while passing through narrowed small vessels.

6. Blood Film Findings

MAHA may produce:

Schistocytes.

These are fragmented red blood cells seen on the peripheral blood film.

Other laboratory findings may include:

Raised LDH.

Reduced haptoglobin.

Raised indirect bilirubin.

Reticulocytosis.

7. Thrombocytopenia

Platelets may also be consumed in the damaged microvasculature.

Therefore, some patients develop:

Thrombocytopenia.

This can make the presentation resemble other thrombotic microangiopathies.

8. Pathophysiology

The fundamental abnormality is severe injury and narrowing of the renal small vessels.

This leads to:

Reduced renal perfusion.

The kidney interprets this as inadequate effective circulation and activates the:

Renin–angiotensin–aldosterone system.

9. Renin Activation

The sequence is:

Renal vascular narrowing → renal ischaemia → renin release → angiotensin II formation → vasoconstriction → aldosterone release → further hypertension.

This creates a vicious cycle of:

Ischaemia + renin activation + worsening hypertension + further vascular damage.

10. Histology

The classic renal histological finding is:

Concentric intimal proliferation of small renal arteries and arterioles.

This produces the characteristic:

“Onion-skin” appearance.

11. Onion-Skin Lesions

The onion-skin appearance reflects:

Concentric thickening of vessel walls.

The lumen becomes markedly narrowed.

This reduces renal blood flow and contributes to:

Renal ischaemia.

Renin release.

Severe hypertension.

12. Interlobular Arteries and Arterioles

The vascular changes particularly affect:

Interlobular arteries

and

Arterioles.

Other changes may include:

Intimal proliferation.

Fibrinoid necrosis in severe cases.

Thrombotic microangiopathic changes.

13. Association with Diffuse Cutaneous Systemic Sclerosis

Scleroderma renal crisis is particularly associated with:

Diffuse cutaneous systemic sclerosis.

Risk is greatest relatively early in the disease course, often within the first few years.

14. Risk Factors

Important risk factors include:

Diffuse skin involvement.

Rapid progression of skin thickening.

Early disease.

Anti-RNA polymerase III antibodies.

Glucocorticoid exposure, especially higher doses.

15. Glucocorticoids

One particularly important association is:

High-dose corticosteroid therapy.

This may increase the risk of scleroderma renal crisis.

Therefore, systemic corticosteroids are used cautiously in systemic sclerosis and, when required for another indication, the lowest appropriate dose is preferred.

16. Anti-RNA Polymerase III

Anti-RNA polymerase III antibodies are strongly associated with:

Diffuse systemic sclerosis

and

Increased risk of scleroderma renal crisis.

This is an important modern addition to older teaching.

17. Treatment

The most important treatment is immediate:

ACE inhibitor therapy.

This should be started promptly when scleroderma renal crisis is suspected.

18. Why ACE Inhibitors Work

ACE inhibitors suppress the overactive:

Renin–angiotensin system.

They reduce:

Angiotensin II-mediated vasoconstriction

and

Aldosterone-mediated sodium retention.

This directly targets one of the central mechanisms driving the crisis.

19. Preferred ACE Inhibitor

A short-acting ACE inhibitor such as:

Captopril

has traditionally been used because it can be titrated rapidly.

Other ACE inhibitors may also be used depending on clinical circumstances and local practice.

20. ACE Inhibitors Should Not Be Withheld Because Creatinine Rises

A particularly important clinical principle is that ACE inhibitors are usually continued despite an initial rise in:

Serum creatinine.

In many other renal conditions, rising creatinine may prompt concern about ACE inhibition.

In scleroderma renal crisis, however, ACE inhibition is central to treatment.

21. Blood Pressure Control

Blood pressure should be lowered carefully but effectively.

The aim is to control:

Severe hypertension

while maintaining adequate organ perfusion.

Additional antihypertensive agents may be required if ACE inhibition alone is insufficient.

22. Dialysis

Some patients develop severe acute kidney injury requiring:

Dialysis.

Indications are the usual severe AKI indications, such as:

Refractory hyperkalaemia.

Severe metabolic acidosis.

Pulmonary oedema.

Uraemic complications.

23. Renal Recovery Can Occur

An important correction to older teaching is that dialysis dependence does not always mean permanent end-stage kidney disease.

Some patients may recover sufficient renal function:

Months after the acute crisis.

Therefore, kidney transplantation is usually not considered immediately after the crisis if recovery remains possible.

24. End-Stage Kidney Disease

Older notes often state:

“Many progress to ESRF.”

This was more accurate before ACE inhibitors became standard treatment.

ACE inhibitor therapy has dramatically improved renal survival and overall prognosis.

Some patients still develop:

End-stage kidney disease

but progression is no longer inevitable.

The preferred modern term is:

End-stage kidney disease, ESKD

rather than ESRF.

25. Kidney Transplantation

If irreversible kidney failure persists, selected patients may eventually undergo:

Kidney transplantation.

Timing depends on:

Duration of dialysis dependence.

Evidence of renal recovery.

Overall systemic sclerosis activity.

Cardiopulmonary status.

26. Systemic Sclerosis Beyond the Kidney

Systemic sclerosis is a multisystem disease.

Other important manifestations include:

Raynaud phenomenon.

Skin thickening and sclerodactyly.

Digital ulcers.

Oesophageal dysmotility and reflux.

Interstitial lung disease.

Pulmonary arterial hypertension.

Cardiac involvement.

27. Diffuse versus Limited Disease

Diffuse cutaneous systemic sclerosis tends to involve more proximal skin and has a higher risk of:

Renal crisis.

Interstitial lung disease.

Cardiac involvement.

Limited cutaneous systemic sclerosis tends to involve distal skin and is classically associated with:

CREST features

and later:

Pulmonary arterial hypertension.

28. Scleroderma Renal Crisis – Note Form

Presentation:

Abrupt severe hypertension.

Acute kidney injury.

Microangiopathic haemolytic anaemia.

Possible thrombocytopenia.

Histology:

Concentric intimal proliferation.

Onion-skin narrowing of interlobular arteries and arterioles.

Mechanism:

Renal vascular injury → renal ischaemia → renin release → severe hypertension.

Risk factors:

Diffuse cutaneous systemic sclerosis.

Early disease.

Rapidly progressive skin thickening.

Anti-RNA polymerase III antibodies.

Higher-dose corticosteroid exposure.

Treatment:

Immediate ACE inhibitor.

Captopril commonly used for rapid titration.

Dialysis if required.

Prognosis:

ACE inhibitors have markedly improved outcomes.

Some patients require dialysis temporarily.

Some progress to permanent end-stage kidney disease.

29. Important Corrections to the Original Notes

The original heading “Systemic sclerosis” is too broad for the renal findings listed.

The specific syndrome is:

Scleroderma renal crisis.

The older term:

Acute renal failure

is better replaced by:

Acute kidney injury.

The statement:

“Many progress to ESRF”

reflects older pre-ACE-inhibitor experience.

Modern treatment with ACE inhibitors has significantly improved renal outcomes, and some dialysis-dependent patients later recover kidney function.

Key Clinical Pattern

Think of scleroderma renal crisis as:

SYSTEMIC SCLEROSIS + SUDDEN SEVERE HYPERTENSION + AKI + MAHA.

The pathology is:

RENAL SMALL-VESSEL NARROWING → “ONION-SKIN” APPEARANCE → RENAL ISCHAEMIA → ↑ RENIN → SEVERE HYPERTENSION.

The treatment to remember is:

ACE INHIBITOR IMMEDIATELY.

And a particularly high-yield association is:

DIFFUSE SYSTEMIC SCLEROSIS + ANTI-RNA POLYMERASE III + HIGH-DOSE STEROIDS → INCREASED RISK OF RENAL CRISIS.